Final overall survival (OS) results from the INAVO120 trial (NCT04191499) confirmed that the addition of inavolisib (Itovebi) ...

As the oncology community prepares for the 2025 American Society of Clinical Oncology Annual Meeting, anticipation is running ...

In an interview, Aditya Shreenivas, MD, MS, discussed the approval of penpulimab in nasopharyngeal carcinoma and the study ...

In an interview, Prof Martin Dreyling discussed the approval of first-line acalabrutinib for the treatment of adult patients ...

Manmeet Ahluwalia, MD, MBA, FASCO, discussed the significance of National Cancer Research Month and highlighted how ongoing ...

Prof Martin Dreyling discusses the safety profile of the BTK inhibitor acalabrutinib in patients with mantle cell lymphoma.

Neel Shah, MD, and Manmeet Ahluwalia, MD, MBA, FASCO, discuss what they look most forward to hearing about and learning at the 2025 ASCO Annual Meeting.

AI-assisted training notably improved pathologist accuracy in HER2-low breast cancer, reducing misclassification and ...

INAVO120 trial shows inavolisib, palbociclib, and fulvestrant significantly improved overall survival in PIK3CA-mutant ...

Long-term data confirms early rituximab significantly delays new treatment for advanced, asymptomatic, low-burden follicular ...

The ODAC deemed the results from TALAPRO-2 are not sufficient to conclude a favorable benefit-risk profile for adding ...

Michael E. Kasper, MD, FACRO, discussed unmet needs in skin cancer treatment and addressed misconceptions among patients and ...